医药产业创新发展持续，关注科创创新药ETF国泰（589720）、创新药ETF国泰（517110）

Group 1: CRO Industry Insights - Since 2025, domestic CRO orders have shown a trend of simultaneous volume and price increase, benefiting from the overseas expansion of innovative drugs and stable financing recovery [1] - Multiple CROs have accelerated new order signing quarterly, achieving double-digit growth in project volume, with a price increase trend observed in experimental monkeys, safety evaluation quotes, and clinical project pricing since Q4 [1] - The performance of CROs is expected to enter an improvement cycle by 2026, driven by strong customer demand and the continuous strengthening of China's global competitiveness in innovative drugs [1] Group 2: Innovative Drug Market Dynamics - Despite previous adjustments in the innovative drug sector, the logic of strengthening global competitiveness, successful overseas expansion, and realization of commercial profits remains unchanged [1] - In the past two years, China has experienced a "big year" for innovative drug overseas expansion, with record highs in both the number and value of licensing-out transactions [1] - In 2025, the number of new drug license-out transactions in China is expected to reach 158, with a total transaction scale of $135.7 billion and an upfront payment scale of $7 billion, marking a ten-year high in both transaction quantity and value [1] Group 3: Brain-Computer Interface (BCI) Developments - The BCI sector is advancing with multiple technological routes underpinned by AI integration and supportive policies, accelerating the commercialization growth cycle [2] - BCIs serve as a direct information exchange channel between the biological brain and external devices, enabling brain function replacement, repair, enhancement, and optimization [2] - In the global landscape, the US leads in invasive technologies while China has made breakthroughs in non-invasive and language decoding fields, with both countries showing minimal technological lag [2] Group 4: Policy and Capital Support for BCI - The BCI industry is included in the "14th Five-Year Plan," with various policies supporting technological innovation, application scenarios, and medical insurance payments, facilitating industry standardization and clinical transformation [2] - Capital investment in the BCI sector has significantly increased, with a multiple growth in financing events and amounts expected by 2025, indicating a strong recovery in investor interest [2] - Although the financing structure shows early-stage characteristics, leading companies have received substantial capital injections, leading to a gradual emergence of industrial clustering effects [2]